NDAORALTABLET
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VASERETIC (enalapril maleate and hydrochlorothiazide) by Bausch + Lomb. Approved for thiazide diuretic [epc]. First approved in 1986.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASERETIC is a fixed-dose combination of enalapril maleate (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) administered orally as a tablet for hypertension management. It combines two complementary mechanisms—vasodilation via ACE inhibition and sodium/fluid reduction via diuresis—to achieve additive blood pressure lowering. This product targets patients requiring dual antihypertensive therapy.
$81KPart D
LOE ApproachingDeclining
Minimal current commercial investment with declining Part D utilization signals a brand team focused on lifecycle maintenance and preparation for generic transition rather than growth initiatives.
Mechanism of Action
Pharmacologic Class:
Thiazide Diuretic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VASERETIC offers limited growth potential; roles are primarily focused on managing market transition, supporting generic conversion, and maximizing remaining branded market share before LOE. This position suits professionals seeking stable, non-growth roles or those transitioning between higher-priority pipeline products.
Brand Manager (portfolio/transition)
Worked on VASERETIC at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.